RVNC—Cantor Fitzgerald initiates coverage with $50 price target: https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Cantor+Fitzgerald+Starts+Revance+Therapeutic+%28RVNC%29+at+Overweight/13116102.html It seems reasonable to infer that CF will be the lead underwriter in the (presumed) near-term financing.